Washington Growth Strategies LLC Has $1.79 Million Position in OPKO Health, Inc. $OPK

Key Points

• Washington Growth Strategies LLC has significantly increased its position in OPKO Health, now owning 1,356,124 shares worth approximately $1.79 million, making it the fund's 17th largest holding.
• OPKO Health's quarterly earnings report revealed a loss of ($0.19) EPS, falling short of estimates, with revenue down 13.9% year-over-year.
• Analyst ratings for OPKO Health vary, with one upgrading the stock to a "strong buy", while others have issued a "hold" or "sell" rating, resulting in an average rating of "Moderate Buy".

Washington Growth Strategies LLC increased its stake in OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 67,806,100.0% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,356,124 shares of the biotechnology company's stock after purchasing an additional 1,356,122 shares during the quarter. OPKO Health makes up 1.4% of Washington Growth Strategies LLC's investment portfolio, making the stock its 17th largest holding. Washington Growth Strategies LLC owned approximately 0.17% of OPKO Health worth $1,790,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in OPKO Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 29,500,071 shares of the biotechnology company's stock worth $48,970,000 after purchasing an additional 293,740 shares during the last quarter. Sculptor Capital LP acquired a new stake in OPKO Health in the 1st quarter worth approximately $21,111,000. Millennium Management LLC lifted its holdings in OPKO Health by 39.2% in the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company's stock worth $10,602,000 after purchasing an additional 1,798,385 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in OPKO Health by 4.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company's stock worth $6,642,000 after purchasing an additional 161,394 shares during the last quarter. Finally, AWM Investment Company Inc. lifted its holdings in OPKO Health by 42.3% in the 1st quarter. AWM Investment Company Inc. now owns 1,850,000 shares of the biotechnology company's stock worth $3,071,000 after purchasing an additional 550,000 shares during the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently weighed in on OPK shares. Weiss Ratings restated a "sell (d-)" rating on shares of OPKO Health in a report on Saturday, September 27th. LADENBURG THALM/SH SH upgraded OPKO Health to a "strong-buy" rating in a report on Tuesday, July 8th. Finally, Zacks Research upgraded OPKO Health from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $2.63.

OPKO Health Stock Up 1.3%

Shares of OPK stock opened at $1.56 on Friday. OPKO Health, Inc. has a 12 month low of $1.11 and a 12 month high of $2.04. The firm has a market cap of $1.24 billion, a PE ratio of -6.24 and a beta of 1.50. The stock has a 50 day moving average of $1.39 and a 200-day moving average of $1.40. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). The firm had revenue of $156.80 million for the quarter, compared to the consensus estimate of $165.74 million. OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The business's revenue for the quarter was down 13.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.01) earnings per share. On average, equities analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current year.

Insider Activity

In other news, CEO Phillip Md Et Al Frost acquired 675,000 shares of the stock in a transaction dated Friday, August 8th. The shares were acquired at an average cost of $1.32 per share, for a total transaction of $891,000.00. Following the completion of the transaction, the chief executive officer owned 214,676,448 shares in the company, valued at approximately $283,372,911.36. This trade represents a 0.32% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 49.69% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OPKO Health, Inc. (NASDAQ:OPK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.